GlassScriptPhysician profile
Urfan A Dar
NPI 1285615260
$10,553.80
in general payments reported to CMS, 2019-2025
23 companies · $1,980 in 2025
The $1,980 reported for 2025 was more than what 78% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,244 · 2020: $911 · 2021: $2,158 · 2022: $1,469 · 2023: $1,727 · 2024: $1,065 · 2025: $1,980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,771.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,530.00 | 2019-2025 | Proclaim, Octrode, Eterna |
| Medtronic, INC. | $2,646.12 | 2021-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim, Synchromedii |
| Boston Scientific Corporation | $756.25 | 2020-2025 | Intracept Rf Probe, Intracept, General - Pain Management |
| Nevro Corp. | $645.85 | 2019-2024 | Senza |
| Globus Medical, INC. | $482.07 | 2025 | Senza |
| Si-Bone, INC. | $298.09 | 2023-2025 | |
| Relievant Medsystems, INC. | $266.91 | 2023 | Intracept |
| Medtronic USA, INC. | $258.78 | 2019-2020 | |
| Spr Therapeutics, INC | $182.55 | 2022-2023 | Sprint Pns System |
| Pfizer INC. | $123.70 | 2019-2021 | |
| Abbvie INC. | $49.99 | 2024 | |
| Mml US, INC. | $41.02 | 2025 | Reactiv8 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.69 | 2020-2024 | Relistor |
| Vertex Pharmaceuticals Incorporated | $33.30 | 2025 | |
| Collegium Pharmaceutical, INC. | $31.84 | 2024 | Nucynta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $26.60 | 2024 | Vegzelma |
| Stryker Corporation | $25.00 | 2019 | |
| Grt US Holding, INC. | $24.32 | 2019 | |
| Redhill Biopharma INC. | $23.31 | 2023 | Talicia |
| Novartis Pharmaceuticals Corporation | $19.31 | 2019 | |
| Curonix LLC | $18.55 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Mdd US Operations, LLC | $16.93 | 2019 | |
| Amgen INC. | $14.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Urfan Dar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.